Rezolute Q3 net loss $18.9M; sunRIZE enrollment on track, BTD for ersodetug

Rezolute, Inc.

2025-Q3 EPS reported -$0.72 vs consensus -$0.27 ▼ miss (-166.4%)

Cash $88.4M at March 31, 2025, down from $127.1M at June 30, 2024.
Phase 3 sunRIZE study enrollment expected to complete May 2025; topline results anticipated December 2025.
FDA granted Breakthrough Therapy Designation to ersodetug for tumor hyperinsulinism hypoglycemia in May 2025.
April 2025 underwritten offering raised ~$97M, extending cash runway to mid-2027.
Appointed Erik Harris (Ultragenyx CCO) to Board of Directors in March 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.